Importantly, CD47‐SIRPα blockade with an anti‐CD47 antibody treatment significantly enhanced EGFR‐targeted cancer therapy and elicited much greater tumor growth inhibition than either treatment alone (Figure 7D). This evidence concerns the gene CD47 and neoplasm.